Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections

• US 6,809,083 B1
• Filed: 02/12/1999
• Issued: 10/26/2004
• Est. Priority Date: 02/12/1998
• Status: Expired due to Term

• Current Assignee: Unither Virology, LLC. (United Therapeutics Corporation)
• Original Assignee: Gary S. Jacob, Martin L. Bryant, Raymond A. Dwek, Richard A. Mueller, Richard A. Partis, Timothy M Block
• Inventors: Dwek, Raymond A., Jacob, Gary S., Block, Timothy M., Mueller, Richard A., Bryant, Martin L., Partis, Richard A.
• Primary Examiner(s): FREDMAN, JEFFREY NORMAN
• Application Number:
  US09/249,220
• Time in Patent Office: 2,083 Days
• Field of Search: 435/5, 514/44, 514/45, 546/88, 546/116, 546/220, 546/243, 546/242
• US Class Current: 514/45
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: C07D 211/46 having a hydrogen atom as the second substituent in position 4

Abstract

Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immuno-stimulating agents.

Claims

1. A method for treating a hepatitis virus infection in a mammal, consisting of administering to said mammal an anti-hepatitis virus effective amount of N-nonyl-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof.

2. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an anti-hepatitis virus effective amount of N-nonyl-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof substantially exclusive of the administration of an antiviral composition comprising a nucleoside, a nucleotide, an immunomodulator, or an immunostimulant.

3. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an anti-hepatitis virus effective amount of N-nonyl-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof substantially exclusive of the administration of other antiviral compounds.